Global Multiple Sclerosis Drugs Market Overview

The Global Multiple Sclerosis Drugs Market size is expected to grow from USD 30.21 billion in 2023 to USD 43.37 billion by 2032, at a CAGR of 4.10% during the forecast period (2024-2032).

Multiple sclerosis (MS) is a chronic neurological disease caused by an unknown inflammatory process in the central nervous system (CNS), resulting in multifocal demyelination and axonal loss primarily in the white matter but also in the grey matter of both the brain and the spinal cord. Clinical manifestations vary depending on the anatomical location of inflammatory lesions and are expressions of acute demyelination, which can resolve completely or partially chronic demyelination, and neuroaxonal injury, which is generally irreversible, or both. Based on whether episodic acute demyelinating events or the chronic neurodegenerative process predominate, the clinical course is classified as either relapsing-remitting, which accounts for approximately 60% of prevalent cases, or progressive.

In 1993, the US Food and Drug Administration approved recombinant interferon (IFN)-1b as the first disease-modifying therapy (DMT) for multiple sclerosis (MS). Interferon-beta (IFNB) 1-a and 1-b, glatiramer acetate (GA), mitoxantrone, natalizumab, fingolimod, teriflunomide, dimethyl fumarate, and alemtuzumab are currently approved disease-modifying therapies (DMTs) for MS by the European Medicine Agency (EMA) and the Food and Drug Administration (FDA).

Market Dynamics And Factors For Multiple Sclerosis Drugs Market

Drivers:

The Rise In Prevalence Of Multiple Sclerosis

Since 2013, the global prevalence of multiple sclerosis has increased. Multiple sclerosis affects an estimated 2.8 million people worldwide (35.9 per 100,000 population). Since 2013, the prevalence of multiple sclerosis has increased in every region of the world, but there are still gaps in prevalence estimates. The average age of diagnosis is 32 years, and the pooled incidence rate across 75 reporting countries is 2.1 per 100,000 people per year. Females are twice as likely as males to have multiple sclerosis. More people living farther from the equator are affected by this. Vitamin D is absorbed by the skin as a result of exposure to sunlight. Researchers are investigating the link between low vitamin D levels and an increased risk of developing multiple sclerosis, an increased frequency of relapses, and a greater negative impact of the disease on patients' lives. Thus, the growing prevalence of multiple sclerosis will bolster the expansion of the multiple sclerosis market during the projected period.

Restraints:

As High-End Drugs Are Administered Treatment of MS Is Expensive

Multiple sclerosis drugs are expensive, according to the National Multiple Sclerosis Society. Multiple sclerosis is a chronic, incurable disease that necessitates lifelong treatment. Despite competition among pharmaceutical companies, the cost of MS drugs remains high, and raising the overall cost of treatment, is expected to hinder the market growth.

Opportunity:

The Rise In Research And Development Of MS Drugs

As the prevalence of multiple sclerosis disease rises, various manufacturers and researchers ramp up their R&D efforts to develop multiple sclerosis drugs. There has been an increase in the development of novel drugs for the treatment of multiple sclerosis in recent years. Recently developed drugs for the treatment of multiple sclerosis include Ponvory, Kesimpta, Bafiertam, Zeposia, Vumerity, Mavenclad, Mayzent, Ocrevus, and Lemtrada. As a result, the market for multiple sclerosis drugs is expected to grow during the forecast period.

Segmentation Analysis Of Multiple Sclerosis Drugs Market

By drug class, the interferon-beta medications segment is forecasted to dominate the multiple sclerosis market in the upcoming future. Interferon-beta drugs are the disease-modifying drugs and the most commonly used drug class for the treatment of multiple sclerosis. Interferon-beta medications help make the disease get worse less often, and they stabilize the course of the disease. These drugs slow disease progression and provide symptom relief. These medications include beta interferon, natalizumab, and glatiramer acetate. These agents are only beneficial to people with relapsing-remitting or secondary progressive MS, not those with primary progressive MS. Subcutaneous (SC) IFN-1b, SC IFN-1a, intramuscular IFN-1a, and SC peginterferon beta-1a are the four IFN drugs currently approved to treat relapsing forms of MS.

By diagnosis, magnetic resonance imaging (MRI) is expected to have the highest share of the hearing aid market in the projected timeframe. The most useful test for confirming the diagnosis of MS is a brain MRI scan. MRI scanning is useful for detecting structural pathology in areas that computed tomography cannot image, such as the posterior fossa, craniometrical junction, and cervical cord. It allows for accurate measurement of disease activity, precise diagnosis, and evaluation of newer therapies. Thus, consolidating the growth of this segment in the projected timeframe.

By route of administration, the oral route segment is forecasted to dominate the multiple sclerosis market in the upcoming future. Oral administration increases patient satisfaction and therapeutic adherence. Three oral medicines for the treatment of multiple sclerosis have been approved by regulatory bodies: fingolimod, teriflunomide, and dimethyl fumarate. For patients with relapsing-remitting MS and secondary progressive MS, oral agents offer novel disease-modifying treatment options.

By distribution channels, Hospital pharmacies have dominated the multiple sclerosis market throughout the forecast period, owing to increased government efforts to strengthen the government hospital pharmacy.

Regional Analysis Of Multiple Sclerosis Drugs Market

The North American region is anticipated to have the highest share of the multiple sclerosis drug market in the forecast period due to the growing awareness of the multiple sclerosis treatment in this region. The easy availability of MS medications and the government's expanded favourable reimbursement policies for MS treatment are factors that contribute to the growth of the Multiple Sclerosis Drugs Market in North America. In the United States, nearly 1 million people have MS. The National Multiple Sclerosis Society estimates that more than 2.8 million people worldwide have MS. MS is most commonly diagnosed between the ages of 20 and 50, but it can strike at any age. Women are more likely than men to develop MS. thus, strengthening the development of the multiple sclerosis drug market during the forecast period.

The Europe region is expected to have the second-highest share of the multiple sclerosis drug market in the projected timeframe, Because of the introduction of new treatment options for multiple sclerosis in the region. Due to increased research and development for drug development in the region, Germany dominates the multiple sclerosis treatment markets in Europe. France is also dominating the market due to increased public awareness of multiple sclerosis treatment.

In Asia Pacific Multiple sclerosis treatment markets are expected to grow in the forecast period due to extensive research and development activity in multiple sclerosis treatment, increasing prevalence of multiple sclerosis, and increasing need for better multiple sclerosis treatment options, which are the major drivers driving market demand in the forecast period.

The Middle East and Africa multiple sclerosis drug markets are expected to be at a significant growth in the projected timeframe, because of increased public awareness of multiple sclerosis and the development and launch of new products COVID-19 cases are on the rise in the Middle East and Africa. This pandemic hampered countries' research and development efforts. Aside from that, a large population is already burdened by noncommunicable diseases such as diabetes and hypertension, making them more vulnerable to the novel coronavirus. These countries are heavily reliant on pharmaceutical products imported from developed countries. As a result, massive supply chain disruptions are impeding the growth of the Middle East and Africa's multiple sclerosis drug markets.

Top Key Players Covered In Multiple Sclerosis Drugs Market

• Biogen (Massachusetts, U.S.)
• Pfizer Inc. (New York, U.S.)
• F. Hoffmann-La Roche Ltd. (Basel, Switzerland)
• Novartis AG (Basel, Switzerland)
• Merck & Co., Inc. (New Jersey, U.S.)
• Sanofi (Paris, France)
• Teva Pharmaceutical Industries Ltd. (Petah Tikva, Israel)
• Bristol-Myers Squibb Company (New York, U.S.) and Other Major Players. 

Key Industry Development In The Multiple Sclerosis Drugs Market

• In February 2024, Roche Pharma India announced the launch of its monoclonal antibody drug, Ocrevus (ocrelizumab), for the treatment of multiple sclerosis. This marked a significant advancement as Ocrevus became the first disease-modifying therapy (DMT) approved for both relapsing multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS) in India. Roche aimed to address the needs of the 150,000-200,000 patients diagnosed with multiple sclerosis in the country.
• In August 2023, The U.S. Food and Drug Administration announced the approved Tyruko (natalizumab-site), marking the first biosimilar to Tysabri (natalizumab) injection for treating adults with relapsing forms of multiple sclerosis (MS). This significant approval allowed for Tyruko to be used in inducing and maintaining clinical response and remission in adult patients with moderately to severely active Crohn’s Disease (CD). Patients eligible for Tyruko had experienced an inadequate response to or were unable to tolerate conventional CD therapies and TNF-α inhibitors.

Chapter 1: Introduction
 1.1 Research Objectives
 1.2 Research Methodology
 1.3 Research Process
 1.4 Scope and Coverage
  1.4.1 Market Definition
  1.4.2 Key Questions Answered
 1.5 Market Segmentation

Chapter 2:Executive Summary

Chapter 3:Growth Opportunities By Segment
 3.1 By Drug Class
 3.2 By Diagnosis
 3.3 By Route of Administrations
 3.4 By Distribution Channels

Chapter 4: Market Landscape
 4.1 Porter's Five Forces Analysis
  4.1.1 Bargaining Power of Supplier
  4.1.2 Threat of New Entrants
  4.1.3 Threat of Substitutes
  4.1.4 Competitive Rivalry
  4.1.5 Bargaining Power Among Buyers
 4.2 Industry Value Chain Analysis
 4.3 Market Dynamics
  4.3.1 Drivers
  4.3.2 Restraints
  4.3.3 Opportunities
  4.5.4 Challenges
 4.4 Pestle Analysis
 4.5 Technological Roadmap
 4.6 Regulatory Landscape
 4.7 SWOT Analysis
 4.8 Price Trend Analysis
 4.9 Patent Analysis
 4.10 Analysis of the Impact of Covid-19
  4.10.1 Impact on the Overall Market
  4.10.2 Impact on the Supply Chain
  4.10.3 Impact on the Key Manufacturers
  4.10.4 Impact on the Pricing

Chapter 5: Multiple Sclerosis Drugs Market by Drug Class
 5.1 Multiple Sclerosis Drugs Market Overview Snapshot and Growth Engine
 5.2 Multiple Sclerosis Drugs Market Overview
 5.3 Immunosuppressants
  5.3.1 Introduction and Market Overview
  5.3.2 Historic and Forecasted Market Size (2017-2032F)
  5.3.3 Key Market Trends, Growth Factors and Opportunities
  5.3.4 Immunosuppressants: Grographic Segmentation
 5.4 Interferon
  5.4.1 Introduction and Market Overview
  5.4.2 Historic and Forecasted Market Size (2017-2032F)
  5.4.3 Key Market Trends, Growth Factors and Opportunities
  5.4.4 Interferon: Grographic Segmentation
 5.5 Others
  5.5.1 Introduction and Market Overview
  5.5.2 Historic and Forecasted Market Size (2017-2032F)
  5.5.3 Key Market Trends, Growth Factors and Opportunities
  5.5.4 Others: Grographic Segmentation

Chapter 6: Multiple Sclerosis Drugs Market by Diagnosis
 6.1 Multiple Sclerosis Drugs Market Overview Snapshot and Growth Engine
 6.2 Multiple Sclerosis Drugs Market Overview
 6.3 Magnetic resonance imaging (MRI)
  6.3.1 Introduction and Market Overview
  6.3.2 Historic and Forecasted Market Size (2017-2032F)
  6.3.3 Key Market Trends, Growth Factors and Opportunities
  6.3.4 Magnetic resonance imaging (MRI): Grographic Segmentation
 6.4 Blood test
  6.4.1 Introduction and Market Overview
  6.4.2 Historic and Forecasted Market Size (2017-2032F)
  6.4.3 Key Market Trends, Growth Factors and Opportunities
  6.4.4 Blood test: Grographic Segmentation
 6.5 Lumbar puncture
  6.5.1 Introduction and Market Overview
  6.5.2 Historic and Forecasted Market Size (2017-2032F)
  6.5.3 Key Market Trends, Growth Factors and Opportunities
  6.5.4 Lumbar puncture: Grographic Segmentation
 6.6 Evoked Potential Test
  6.6.1 Introduction and Market Overview
  6.6.2 Historic and Forecasted Market Size (2017-2032F)
  6.6.3 Key Market Trends, Growth Factors and Opportunities
  6.6.4 Evoked Potential Test: Grographic Segmentation

Chapter 7: Multiple Sclerosis Drugs Market by Route of Administrations
 7.1 Multiple Sclerosis Drugs Market Overview Snapshot and Growth Engine
 7.2 Multiple Sclerosis Drugs Market Overview
 7.3 Injection
  7.3.1 Introduction and Market Overview
  7.3.2 Historic and Forecasted Market Size (2017-2032F)
  7.3.3 Key Market Trends, Growth Factors and Opportunities
  7.3.4 Injection: Grographic Segmentation
 7.4 Oral
  7.4.1 Introduction and Market Overview
  7.4.2 Historic and Forecasted Market Size (2017-2032F)
  7.4.3 Key Market Trends, Growth Factors and Opportunities
  7.4.4 Oral: Grographic Segmentation
 7.5 Others
  7.5.1 Introduction and Market Overview
  7.5.2 Historic and Forecasted Market Size (2017-2032F)
  7.5.3 Key Market Trends, Growth Factors and Opportunities
  7.5.4 Others: Grographic Segmentation

Chapter 8: Multiple Sclerosis Drugs Market by Distribution Channels
 8.1 Multiple Sclerosis Drugs Market Overview Snapshot and Growth Engine
 8.2 Multiple Sclerosis Drugs Market Overview
 8.3 Online Pharmacy
  8.3.1 Introduction and Market Overview
  8.3.2 Historic and Forecasted Market Size (2017-2032F)
  8.3.3 Key Market Trends, Growth Factors and Opportunities
  8.3.4 Online Pharmacy: Grographic Segmentation
 8.4 Hospital Pharmacy
  8.4.1 Introduction and Market Overview
  8.4.2 Historic and Forecasted Market Size (2017-2032F)
  8.4.3 Key Market Trends, Growth Factors and Opportunities
  8.4.4 Hospital Pharmacy: Grographic Segmentation
 8.5 Retail Pharmacy
  8.5.1 Introduction and Market Overview
  8.5.2 Historic and Forecasted Market Size (2017-2032F)
  8.5.3 Key Market Trends, Growth Factors and Opportunities
  8.5.4 Retail Pharmacy: Grographic Segmentation

Chapter 9: Company Profiles and Competitive Analysis
 9.1 Competitive Landscape
  9.1.1 Competitive Positioning
  9.1.2 Multiple Sclerosis Drugs Sales and Market Share By Players
  9.1.3 Industry BCG Matrix
  9.1.4 Ansoff Matrix
  9.1.5 Multiple Sclerosis Drugs Industry Concentration Ratio (CR5 and HHI)
  9.1.6 Top 5 Multiple Sclerosis Drugs Players Market Share
  9.1.7 Mergers and Acquisitions
  9.1.8 Business Strategies By Top Players
 9.2 BIOGEN
  9.2.1 Company Overview
  9.2.2 Key Executives
  9.2.3 Company Snapshot
  9.2.4 Operating Business Segments
  9.2.5 Product Portfolio
  9.2.6 Business Performance
  9.2.7 Key Strategic Moves and Recent Developments
  9.2.8 SWOT Analysis
 9.3 PFIZER INC.
 9.4 F. HOFFMANN-LA ROCHE LTD.
 9.5 NOVARTIS AG
 9.6 MERCK & CO. INC.
 9.7 SANOFI
 9.8 TEVA PHARMACEUTICAL INDUSTRIES LTD.
 9.9 BRISTOL-MYERS SQUIBB COMPANY
 9.10 OTHER MAJOR PLAYERS

Chapter 10: Global Multiple Sclerosis Drugs Market Analysis, Insights and Forecast, 2017-2032
 10.1 Market Overview
 10.2 Historic and Forecasted Market Size By Drug Class
  10.2.1 Immunosuppressants
  10.2.2 Interferon
  10.2.3 Others
 10.3 Historic and Forecasted Market Size By Diagnosis
  10.3.1 Magnetic resonance imaging (MRI)
  10.3.2 Blood test
  10.3.3 Lumbar puncture
  10.3.4 Evoked Potential Test
 10.4 Historic and Forecasted Market Size By Route of Administrations
  10.4.1 Injection
  10.4.2 Oral
  10.4.3 Others
 10.5 Historic and Forecasted Market Size By Distribution Channels
  10.5.1 Online Pharmacy
  10.5.2 Hospital Pharmacy
  10.5.3 Retail Pharmacy

Chapter 11: North America Multiple Sclerosis Drugs Market Analysis, Insights and Forecast, 2017-2032
 11.1 Key Market Trends, Growth Factors and Opportunities
 11.2 Impact of Covid-19
 11.3 Key Players
 11.4 Key Market Trends, Growth Factors and Opportunities
 11.4 Historic and Forecasted Market Size By Drug Class
  11.4.1 Immunosuppressants
  11.4.2 Interferon
  11.4.3 Others
 11.5 Historic and Forecasted Market Size By Diagnosis
  11.5.1 Magnetic resonance imaging (MRI)
  11.5.2 Blood test
  11.5.3 Lumbar puncture
  11.5.4 Evoked Potential Test
 11.6 Historic and Forecasted Market Size By Route of Administrations
  11.6.1 Injection
  11.6.2 Oral
  11.6.3 Others
 11.7 Historic and Forecasted Market Size By Distribution Channels
  11.7.1 Online Pharmacy
  11.7.2 Hospital Pharmacy
  11.7.3 Retail Pharmacy
 11.8 Historic and Forecast Market Size by Country
  11.8.1 U.S.
  11.8.2 Canada
  11.8.3 Mexico

Chapter 12: Europe Multiple Sclerosis Drugs Market Analysis, Insights and Forecast, 2017-2032
 12.1 Key Market Trends, Growth Factors and Opportunities
 12.2 Impact of Covid-19
 12.3 Key Players
 12.4 Key Market Trends, Growth Factors and Opportunities
 12.4 Historic and Forecasted Market Size By Drug Class
  12.4.1 Immunosuppressants
  12.4.2 Interferon
  12.4.3 Others
 12.5 Historic and Forecasted Market Size By Diagnosis
  12.5.1 Magnetic resonance imaging (MRI)
  12.5.2 Blood test
  12.5.3 Lumbar puncture
  12.5.4 Evoked Potential Test
 12.6 Historic and Forecasted Market Size By Route of Administrations
  12.6.1 Injection
  12.6.2 Oral
  12.6.3 Others
 12.7 Historic and Forecasted Market Size By Distribution Channels
  12.7.1 Online Pharmacy
  12.7.2 Hospital Pharmacy
  12.7.3 Retail Pharmacy
 12.8 Historic and Forecast Market Size by Country
  12.8.1 Germany
  12.8.2 U.K.
  12.8.3 France
  12.8.4 Italy
  12.8.5 Russia
  12.8.6 Spain
  12.8.7 Rest of Europe

Chapter 13: Asia-Pacific Multiple Sclerosis Drugs Market Analysis, Insights and Forecast, 2017-2032
 13.1 Key Market Trends, Growth Factors and Opportunities
 13.2 Impact of Covid-19
 13.3 Key Players
 13.4 Key Market Trends, Growth Factors and Opportunities
 13.4 Historic and Forecasted Market Size By Drug Class
  13.4.1 Immunosuppressants
  13.4.2 Interferon
  13.4.3 Others
 13.5 Historic and Forecasted Market Size By Diagnosis
  13.5.1 Magnetic resonance imaging (MRI)
  13.5.2 Blood test
  13.5.3 Lumbar puncture
  13.5.4 Evoked Potential Test
 13.6 Historic and Forecasted Market Size By Route of Administrations
  13.6.1 Injection
  13.6.2 Oral
  13.6.3 Others
 13.7 Historic and Forecasted Market Size By Distribution Channels
  13.7.1 Online Pharmacy
  13.7.2 Hospital Pharmacy
  13.7.3 Retail Pharmacy
 13.8 Historic and Forecast Market Size by Country
  13.8.1 China
  13.8.2 India
  13.8.3 Japan
  13.8.4 Singapore
  13.8.5 Australia
  13.8.6 New Zealand
  13.8.7 Rest of APAC

Chapter 14: Middle East & Africa Multiple Sclerosis Drugs Market Analysis, Insights and Forecast, 2017-2032
 14.1 Key Market Trends, Growth Factors and Opportunities
 14.2 Impact of Covid-19
 14.3 Key Players
 14.4 Key Market Trends, Growth Factors and Opportunities
 14.4 Historic and Forecasted Market Size By Drug Class
  14.4.1 Immunosuppressants
  14.4.2 Interferon
  14.4.3 Others
 14.5 Historic and Forecasted Market Size By Diagnosis
  14.5.1 Magnetic resonance imaging (MRI)
  14.5.2 Blood test
  14.5.3 Lumbar puncture
  14.5.4 Evoked Potential Test
 14.6 Historic and Forecasted Market Size By Route of Administrations
  14.6.1 Injection
  14.6.2 Oral
  14.6.3 Others
 14.7 Historic and Forecasted Market Size By Distribution Channels
  14.7.1 Online Pharmacy
  14.7.2 Hospital Pharmacy
  14.7.3 Retail Pharmacy
 14.8 Historic and Forecast Market Size by Country
  14.8.1 Turkey
  14.8.2 Saudi Arabia
  14.8.3 Iran
  14.8.4 UAE
  14.8.5 Africa
  14.8.6 Rest of MEA

Chapter 15: South America Multiple Sclerosis Drugs Market Analysis, Insights and Forecast, 2017-2032
 15.1 Key Market Trends, Growth Factors and Opportunities
 15.2 Impact of Covid-19
 15.3 Key Players
 15.4 Key Market Trends, Growth Factors and Opportunities
 15.4 Historic and Forecasted Market Size By Drug Class
  15.4.1 Immunosuppressants
  15.4.2 Interferon
  15.4.3 Others
 15.5 Historic and Forecasted Market Size By Diagnosis
  15.5.1 Magnetic resonance imaging (MRI)
  15.5.2 Blood test
  15.5.3 Lumbar puncture
  15.5.4 Evoked Potential Test
 15.6 Historic and Forecasted Market Size By Route of Administrations
  15.6.1 Injection
  15.6.2 Oral
  15.6.3 Others
 15.7 Historic and Forecasted Market Size By Distribution Channels
  15.7.1 Online Pharmacy
  15.7.2 Hospital Pharmacy
  15.7.3 Retail Pharmacy
 15.8 Historic and Forecast Market Size by Country
  15.8.1 Brazil
  15.8.2 Argentina
  15.8.3 Rest of SA

Chapter 16 Investment Analysis

Chapter 17 Analyst Viewpoint and Conclusion

LIST OF TABLES

TABLE 001. EXECUTIVE SUMMARY
TABLE 002. MULTIPLE SCLEROSIS DRUGS MARKET BARGAINING POWER OF SUPPLIERS
TABLE 003. MULTIPLE SCLEROSIS DRUGS MARKET BARGAINING POWER OF CUSTOMERS
TABLE 004. MULTIPLE SCLEROSIS DRUGS MARKET COMPETITIVE RIVALRY
TABLE 005. MULTIPLE SCLEROSIS DRUGS MARKET THREAT OF NEW ENTRANTS
TABLE 006. MULTIPLE SCLEROSIS DRUGS MARKET THREAT OF SUBSTITUTES
TABLE 007. MULTIPLE SCLEROSIS DRUGS MARKET BY DRUG CLASS
TABLE 008. IMMUNOSUPPRESSANTS MARKET OVERVIEW (2016-2028)
TABLE 009. INTERFERON MARKET OVERVIEW (2016-2028)
TABLE 010. OTHERS MARKET OVERVIEW (2016-2028)
TABLE 011. MULTIPLE SCLEROSIS DRUGS MARKET BY DIAGNOSIS
TABLE 012. MAGNETIC RESONANCE IMAGING (MRI) MARKET OVERVIEW (2016-2028)
TABLE 013. BLOOD TEST MARKET OVERVIEW (2016-2028)
TABLE 014. LUMBAR PUNCTURE MARKET OVERVIEW (2016-2028)
TABLE 015. EVOKED POTENTIAL TEST MARKET OVERVIEW (2016-2028)
TABLE 016. MULTIPLE SCLEROSIS DRUGS MARKET BY ROUTE OF ADMINISTRATIONS
TABLE 017. INJECTION MARKET OVERVIEW (2016-2028)
TABLE 018. ORAL MARKET OVERVIEW (2016-2028)
TABLE 019. OTHERS MARKET OVERVIEW (2016-2028)
TABLE 020. MULTIPLE SCLEROSIS DRUGS MARKET BY DISTRIBUTION CHANNELS
TABLE 021. ONLINE PHARMACY MARKET OVERVIEW (2016-2028)
TABLE 022. HOSPITAL PHARMACY MARKET OVERVIEW (2016-2028)
TABLE 023. RETAIL PHARMACY MARKET OVERVIEW (2016-2028)
TABLE 024. NORTH AMERICA MULTIPLE SCLEROSIS DRUGS MARKET, BY DRUG CLASS (2016-2028)
TABLE 025. NORTH AMERICA MULTIPLE SCLEROSIS DRUGS MARKET, BY DIAGNOSIS (2016-2028)
TABLE 026. NORTH AMERICA MULTIPLE SCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATIONS (2016-2028)
TABLE 027. NORTH AMERICA MULTIPLE SCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNELS (2016-2028)
TABLE 028. N MULTIPLE SCLEROSIS DRUGS MARKET, BY COUNTRY (2016-2028)
TABLE 029. EUROPE MULTIPLE SCLEROSIS DRUGS MARKET, BY DRUG CLASS (2016-2028)
TABLE 030. EUROPE MULTIPLE SCLEROSIS DRUGS MARKET, BY DIAGNOSIS (2016-2028)
TABLE 031. EUROPE MULTIPLE SCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATIONS (2016-2028)
TABLE 032. EUROPE MULTIPLE SCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNELS (2016-2028)
TABLE 033. MULTIPLE SCLEROSIS DRUGS MARKET, BY COUNTRY (2016-2028)
TABLE 034. ASIA PACIFIC MULTIPLE SCLEROSIS DRUGS MARKET, BY DRUG CLASS (2016-2028)
TABLE 035. ASIA PACIFIC MULTIPLE SCLEROSIS DRUGS MARKET, BY DIAGNOSIS (2016-2028)
TABLE 036. ASIA PACIFIC MULTIPLE SCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATIONS (2016-2028)
TABLE 037. ASIA PACIFIC MULTIPLE SCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNELS (2016-2028)
TABLE 038. MULTIPLE SCLEROSIS DRUGS MARKET, BY COUNTRY (2016-2028)
TABLE 039. MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS DRUGS MARKET, BY DRUG CLASS (2016-2028)
TABLE 040. MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS DRUGS MARKET, BY DIAGNOSIS (2016-2028)
TABLE 041. MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATIONS (2016-2028)
TABLE 042. MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNELS (2016-2028)
TABLE 043. MULTIPLE SCLEROSIS DRUGS MARKET, BY COUNTRY (2016-2028)
TABLE 044. SOUTH AMERICA MULTIPLE SCLEROSIS DRUGS MARKET, BY DRUG CLASS (2016-2028)
TABLE 045. SOUTH AMERICA MULTIPLE SCLEROSIS DRUGS MARKET, BY DIAGNOSIS (2016-2028)
TABLE 046. SOUTH AMERICA MULTIPLE SCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATIONS (2016-2028)
TABLE 047. SOUTH AMERICA MULTIPLE SCLEROSIS DRUGS MARKET, BY DISTRIBUTION CHANNELS (2016-2028)
TABLE 048. MULTIPLE SCLEROSIS DRUGS MARKET, BY COUNTRY (2016-2028)
TABLE 049. BIOGEN: SNAPSHOT
TABLE 050. BIOGEN: BUSINESS PERFORMANCE
TABLE 051. BIOGEN: PRODUCT PORTFOLIO
TABLE 052. BIOGEN: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 052. PFIZER INC.: SNAPSHOT
TABLE 053. PFIZER INC.: BUSINESS PERFORMANCE
TABLE 054. PFIZER INC.: PRODUCT PORTFOLIO
TABLE 055. PFIZER INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 055. F. HOFFMANN-LA ROCHE LTD.: SNAPSHOT
TABLE 056. F. HOFFMANN-LA ROCHE LTD.: BUSINESS PERFORMANCE
TABLE 057. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
TABLE 058. F. HOFFMANN-LA ROCHE LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 058. NOVARTIS AG: SNAPSHOT
TABLE 059. NOVARTIS AG: BUSINESS PERFORMANCE
TABLE 060. NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 061. NOVARTIS AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 061. MERCK & CO. INC.: SNAPSHOT
TABLE 062. MERCK & CO. INC.: BUSINESS PERFORMANCE
TABLE 063. MERCK & CO. INC.: PRODUCT PORTFOLIO
TABLE 064. MERCK & CO. INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 064. SANOFI: SNAPSHOT
TABLE 065. SANOFI: BUSINESS PERFORMANCE
TABLE 066. SANOFI: PRODUCT PORTFOLIO
TABLE 067. SANOFI: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 067. TEVA PHARMACEUTICAL INDUSTRIES LTD.: SNAPSHOT
TABLE 068. TEVA PHARMACEUTICAL INDUSTRIES LTD.: BUSINESS PERFORMANCE
TABLE 069. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
TABLE 070. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 070. BRISTOL-MYERS SQUIBB COMPANY: SNAPSHOT
TABLE 071. BRISTOL-MYERS SQUIBB COMPANY: BUSINESS PERFORMANCE
TABLE 072. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT PORTFOLIO
TABLE 073. BRISTOL-MYERS SQUIBB COMPANY: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 073. OTHER MAJOR PLAYERS: SNAPSHOT
TABLE 074. OTHER MAJOR PLAYERS: BUSINESS PERFORMANCE
TABLE 075. OTHER MAJOR PLAYERS: PRODUCT PORTFOLIO
TABLE 076. OTHER MAJOR PLAYERS: KEY STRATEGIC MOVES AND DEVELOPMENTS

LIST OF FIGURES

FIGURE 001. YEARS CONSIDERED FOR ANALYSIS
FIGURE 002. SCOPE OF THE STUDY
FIGURE 003. MULTIPLE SCLEROSIS DRUGS MARKET OVERVIEW BY REGIONS
FIGURE 004. PORTER'S FIVE FORCES ANALYSIS
FIGURE 005. BARGAINING POWER OF SUPPLIERS
FIGURE 006. COMPETITIVE RIVALRYFIGURE 007. THREAT OF NEW ENTRANTS
FIGURE 008. THREAT OF SUBSTITUTES
FIGURE 009. VALUE CHAIN ANALYSIS
FIGURE 010. PESTLE ANALYSIS
FIGURE 011. MULTIPLE SCLEROSIS DRUGS MARKET OVERVIEW BY DRUG CLASS
FIGURE 012. IMMUNOSUPPRESSANTS MARKET OVERVIEW (2016-2028)
FIGURE 013. INTERFERON MARKET OVERVIEW (2016-2028)
FIGURE 014. OTHERS MARKET OVERVIEW (2016-2028)
FIGURE 015. MULTIPLE SCLEROSIS DRUGS MARKET OVERVIEW BY DIAGNOSIS
FIGURE 016. MAGNETIC RESONANCE IMAGING (MRI) MARKET OVERVIEW (2016-2028)
FIGURE 017. BLOOD TEST MARKET OVERVIEW (2016-2028)
FIGURE 018. LUMBAR PUNCTURE MARKET OVERVIEW (2016-2028)
FIGURE 019. EVOKED POTENTIAL TEST MARKET OVERVIEW (2016-2028)
FIGURE 020. MULTIPLE SCLEROSIS DRUGS MARKET OVERVIEW BY ROUTE OF ADMINISTRATIONS
FIGURE 021. INJECTION MARKET OVERVIEW (2016-2028)
FIGURE 022. ORAL MARKET OVERVIEW (2016-2028)
FIGURE 023. OTHERS MARKET OVERVIEW (2016-2028)
FIGURE 024. MULTIPLE SCLEROSIS DRUGS MARKET OVERVIEW BY DISTRIBUTION CHANNELS
FIGURE 025. ONLINE PHARMACY MARKET OVERVIEW (2016-2028)
FIGURE 026. HOSPITAL PHARMACY MARKET OVERVIEW (2016-2028)
FIGURE 027. RETAIL PHARMACY MARKET OVERVIEW (2016-2028)
FIGURE 028. NORTH AMERICA MULTIPLE SCLEROSIS DRUGS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 029. EUROPE MULTIPLE SCLEROSIS DRUGS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 030. ASIA PACIFIC MULTIPLE SCLEROSIS DRUGS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 031. MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS DRUGS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 032. SOUTH AMERICA MULTIPLE SCLEROSIS DRUGS MARKET OVERVIEW BY COUNTRY (2016-2028)